Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celularity (CELUW) EBITDA (2020 - 2025)

Historic EBITDA for Celularity (CELUW) over the last 6 years, with Q3 2025 value amounting to -$23.1 million.

  • Celularity's EBITDA fell 4331.06% to -$23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.6 million, marking a year-over-year decrease of 11534.62%. This contributed to the annual value of -$57.9 million for FY2024, which is 7048.32% up from last year.
  • Latest data reveals that Celularity reported EBITDA of -$23.1 million as of Q3 2025, which was down 4331.06% from -$24.5 million recorded in Q2 2025.
  • In the past 5 years, Celularity's EBITDA registered a high of $49.9 million during Q3 2021, and its lowest value of -$93.9 million during Q3 2023.
  • For the 5-year period, Celularity's EBITDA averaged around -$19.3 million, with its median value being -$19.7 million (2025).
  • Within the past 5 years, the most significant YoY rise in Celularity's EBITDA was 113907.62% (2021), while the steepest drop was 2900729.81% (2021).
  • Quarter analysis of 5 years shows Celularity's EBITDA stood at -$4.0 million in 2021, then soared by 699.18% to $24.2 million in 2022, then crashed by 70.45% to $7.2 million in 2023, then tumbled by 285.91% to -$13.3 million in 2024, then plummeted by 73.53% to -$23.1 million in 2025.
  • Its EBITDA stands at -$23.1 million for Q3 2025, versus -$24.5 million for Q2 2025 and -$19.7 million for Q1 2025.